Teva Pharmaceutical has announced the Food and Drug Administration (FDA) approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States.
Teva is preparing to launch the product in the near future.
Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the United States, according to IMS data as of November 2014.
